Take­da to com­mer­cial­ize Im­muno­Gen’s Ela­here in Japan; Val­ne­va shares safe­ty da­ta for its chikun­gun­ya vac­cine

Take­da plans to pay Im­muno­Gen $34 mil­lion as part of a deal to de­vel­op and com­mer­cial­ize Im­muno­Gen’s can­cer treat­ment Ela­here in Japan.

Im­muno­Gen re­tains ex­clu­sive pro­duc­tion rights for Ela­here and can al­so get oth­er mile­stone pay­ments and a piece of Ela­here’s net sales in Japan.

Part of the $34 mil­lion could in­clude a mile­stone pay­ment for Im­muno­Gen if Ela­here’s ac­cel­er­at­ed ap­proval in plat­inum-re­sis­tant ovar­i­an can­cer in No­vem­ber is con­vert­ed to a full FDA ap­proval. A con­fir­ma­to­ry tri­al in May showed the drug re­duced the risk of death by 33% com­pared to chemo in pa­tients with ad­vanced ovar­i­an can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER